Esophageal cancer risk assessment method

Abstract

The invention discloses an esophageal cancer risk assessment method, and belongs to the field of esophageal cancer risk assessment, and the method comprises the steps: quantifying diet pathogenic factors in a region based on the content mean value of nitrosamine compounds in saliva of an initial patient in the region; the method comprises the following steps: acquiring symptoms of early, middle and late patients, performing principal component analysis to obtain a symptom set, and acquiring correlation between various symptom combinations in the symptom set and esophageal cancer; acquiring symptoms of the to-be-detected object and the content of nitrosamine compounds in saliva; matching the symptoms of the to-be-examined object with the symptoms in the symptom set to obtain a matching result; and according to the matching result, the correlation between various symptom combinations in the symptom set and the esophageal cancer and the content of nitrosamine compounds in the saliva of the to-be-inspected object, obtaining a disease risk value of the to-be-inspected object. According to the method, regional dietary habits are quantified, symptom matching is combined, the disease risk value of the to-be-examined person is calculated, and diagnosis of a doctor is facilitated.

Description

Technical Field

[0001] The present invention belongs to the field of esophageal cancer risk assessment, and in particular relates to an esophageal cancer risk assessment method. Background Art

[0002] Esophageal cancer is one of the most common malignant tumors in the world, with high incidence, poor prognosis, and difficulty in early diagnosis. According to global cancer statistics, esophageal cancer ranks seventh and sixth in global cancer incidence and mortality, respectively. Although significant progress has been made in the treatment of esophageal cancer in recent years, most patients are already in the middle and late stages when diagnosed due to its unclear early symptoms, resulting in a low survival rate. Therefore, how to detect and accurately diagnose esophageal cancer early has become an urgent problem to be solved. In the western region, the economic and cultural levels are relatively backward, and the foundation for cancer prevention and control is weak. According to the survey results in the 1970s (1970-1974), the end of the 1990s (1990-1992), and 2004-2005, the mortality rate of esophageal cancer has been rising in stages, which has seriously affected people's quality of life and life expectancy, caused the loss of human and social resources, and brought immeasurable economic and mental losses to patients and their families. Therefore, cancer screening has become the key to improving patient prognosis and survival. The development of big data technology has provided a new opportunity for the study of esophageal cancer. Constructing a large esophageal cancer model based on big data will help achieve precision medicine for esophageal cancer.

[0003] Traditional diagnostic methods such as endoscopy and tissue biopsy are accurate, but difficult to popularize due to their complex operation and high cost. Although the current multi-dimensional omics-based analysis has improved the accuracy of patient diagnosis and prognosis, its high cost makes it out of reach for ordinary people. Summary of the invention

[0004] In view of the above-mentioned deficiencies in the prior art, the present invention provides an esophageal cancer risk assessment method which quantifies regional dietary habits and combines symptom matching to calculate the disease risk value of the person being examined, thereby facilitating diagnosis by doctors.

[0005] In order to achieve the above-mentioned purpose of the invention, the technical solution adopted by the present invention is: a method for assessing the risk of esophageal cancer, comprising the following steps:

[0006] S1. Quantify the dietary pathogenic factors in the region based on the mean content of nitrosamine compounds in the saliva of early patients in the region;

[0007] S2. Obtain the symptoms of patients in the early, middle and late stages, and perform principal component analysis to obtain a symptom set, and obtain the correlation between various symptom combinations in the symptom set and esophageal cancer;

[0008] S3, obtaining the symptoms of the subject to be examined and the content of nitrosamine compounds in saliva;

[0009] S4, matching the symptoms of the subject to be examined with the symptoms in the symptom set to obtain a matching result;

[0010] S5. Obtain the disease risk value of the subject to be examined according to the matching result, the correlation between various symptom combinations in the symptom set and esophageal cancer, and the content of nitrosamine compounds in the saliva of the subject to be examined. When the disease risk value of the subject to be examined is greater than a preset risk threshold, the subject to be examined has a high risk of esophageal cancer; otherwise, the subject to be examined has a low risk of esophageal cancer. The expression of the disease risk value of the subject to be examined is:

[0011]

[0012] Wherein, P is the disease risk value of the subject to be examined; MMN is the normalization function; max is the maximum value function; R is the correlation between each symptom combination in the initial symptom combination set and esophageal cancer; V is the content of nitrosamine compounds in the saliva of the subject to be examined; Y is the age of the subject to be examined; It is the annual average value of the content in initial patients in the region.

[0013] Furthermore, the step S1 is specifically as follows:

[0014] S101, obtaining sample data of N initial patients in a region to obtain an initial sample set;

[0015] S102, based on age, remove discrete samples in the initial sample set to obtain a sample set concentrated in the age group;

[0016] S103. The mean age of the patients in the sample set in the age group is taken as the mean age of the initial patients in the region;

[0017] S104, calculating the mean value of the nitrosamine compound content in the saliva of the patients in the sample set of the age group as the control value of the nitrosamine compound content of the patients in the region;

[0018] S105. For each patient in the initial sample set, the ratio of the nitrosamine compound content in the patient's saliva to the control nitrosamine compound content of patients in the region is used as the weight of the patient's dietary habits;

[0019] S106. Based on the weight of the dietary habits of each patient in the initial sample set, the dietary pathogenic factors of the region are quantified using the annual average of the content of initial patients in the region.

[0020] Furthermore, the expression of the mean age of the initial patients in the region in step S103 is:

[0021]

[0022] Among them, Y N1 is the mean age of the initial patients in the region; min_x N1 The minimum age of the initial patients in the region; max_x N1 is the maximum age of the initial patients in the region; num(x N1 ) is age x N1 The number of patients; x N1 is age; ε1 is the age balance coefficient.

[0023] Furthermore, the expression of the annual average value of the content of the initial patients in the region in step S106 is:

[0024]

[0025] in, Y is the annual average value of the content of initial patients in the region; N1 is the mean age of the initial patients in the region; min_x N1 The minimum age of the initial patients in the region; max_x N1 is the maximum age of the initial patients in the region; ε1 is the age balance coefficient; V i1 is the content of nitrosamine compounds in the saliva of the i1th patient in the initial sample set; N1 is the total number of patients in the initial sample set; i1 is the patient number in the initial sample set.

[0026] Furthermore, the correlation between various symptom combinations in the symptom set and esophageal cancer obtained in step S2 is specifically:

[0027] A1. Obtain a set of various symptom combinations in the symptom set, that is, a symptom combination sequence set;

[0028] A2. For each symptom combination in the symptom combination sequence set, obtain the ratio of the symptoms in the symptom combination that co-occur in the patients sampled in step S2 as the correlation between the symptom combination and esophageal cancer.

[0029] Furthermore, the step S5 is specifically as follows:

[0030] S501, obtaining an initial symptom combination set according to possible combinations of various symptoms in the matching results;

[0031] S502, according to the initial symptom combination set, based on the correlations between various symptom combinations in the symptom set and esophageal cancer, obtaining the correlations between each symptom combination in the initial symptom combination set and esophageal cancer;

[0032] S503. Obtain the disease risk value of the subject to be examined according to the correlation between each symptom combination in the initial symptom combination set and esophageal cancer and the content of nitrosamine compounds in the saliva of the subject to be examined.

[0033] The beneficial effects of the present invention are as follows: the present invention realizes the quantification of regional diet through the content of nitrosamine compounds, estimates the correlation between symptoms of esophageal cancer and esophageal cancer, calculates the risk of disease based on the correlation of symptoms and the quantification of diet, and reduces the medical burden. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 The present invention is a flow chart of the method. DETAILED DESCRIPTION

[0035] The specific implementation modes of the present invention are described below so that those skilled in the art can understand the present invention. However, it should be clear that the present invention is not limited to the scope of the specific implementation modes. For those of ordinary skill in the art, as long as various changes are within the spirit and scope of the present invention as defined and determined by the attached claims, these changes are obvious, and all inventions and creations utilizing the concept of the present invention are protected.

[0036] like Figure 1 As shown, in one embodiment of the present invention, a method for assessing the risk of esophageal cancer comprises the following steps:

[0037] S1. Quantify the dietary pathogenic factors in the region based on the mean content of nitrosamine compounds in the saliva of early patients in the region;

[0038] S2. Obtain the symptoms of patients in the early, middle and late stages, and perform principal component analysis to obtain a symptom set, and obtain the correlation between various symptom combinations in the symptom set and esophageal cancer;

[0039] S3, obtaining the symptoms of the subject to be examined and the content of nitrosamine compounds in saliva;

[0040] S4, matching the symptoms of the subject to be examined with the symptoms in the symptom set to obtain a matching result;

[0041] S5. Obtain the disease risk value of the subject to be examined according to the matching result, the correlation between various symptom combinations in the symptom set and esophageal cancer, and the content of nitrosamine compounds in the saliva of the subject to be examined. When the disease risk value of the subject to be examined is greater than a preset risk threshold, the subject to be examined has a high risk of esophageal cancer; otherwise, the subject to be examined has a low risk of esophageal cancer. The expression of the disease risk value of the subject to be examined is:

[0042]

[0043] Wherein, P is the disease risk value of the subject to be examined; MMN is the normalization function; max is the maximum value function; R is the correlation between each symptom combination in the initial symptom combination set and esophageal cancer; V is the content of nitrosamine compounds in the saliva of the subject to be examined; Y is the age of the subject to be examined; It is the annual average value of the content in initial patients in the region.

[0044] Among the causes of esophageal cancer, the intake of nitrosamine compounds is an important factor. In areas with a high incidence of esophageal cancer, the content of nitrite in diet, drinking water, pickled vegetables and saliva of patients is higher than that in areas with a low incidence. Different places have different living and eating habits, and the content of nitrosamine compounds in the body is also different, but the importance of nitrosamine compounds in the causes of disease in patients in the same area is also different.

[0045] In order to quantify the dietary habits in the region, it is necessary to collect the content of nitrosamine compounds in the saliva of several early patients from various locations.

[0046] In this embodiment, the so-called early stage patients refer specifically to the patient status at the time of discovery. For example, a patient who is in the early stage at the time of discovery and subsequently deteriorates to the late stage is sampled as an early stage patient in this embodiment, and the nitrosamine compound content of the patient at the time of discovery is collected. This is done to avoid the patient's intake control of nitrosamine compounds during treatment affecting the patient's nitrosamine compound content.

[0047] Specifically, the content of nitrosamine compounds in the bodies of N early esophageal cancer patients was collected in each region, and the patients who were too young and too old were eliminated (achieved by using the age balance coefficient), and the mean age of the early patients was calculated; for early patients, the ratio of the content of nitrosamine compounds in the patient's body to the mean content of early patients after excluding the age error was used as the pathogenic influence weight of nitrosamine compounds in the patient, and the mean content of early patients was calculated based on the pathogenic influence weight.

[0048] The early stage patients in step S1 specifically refer to patients whose disease stage is in the early stage when they are discovered.

[0049] The step S1 is specifically as follows:

[0050] S101, obtaining sample data of N initial patients in a region to obtain an initial sample set;

[0051] S102, based on age, remove discrete samples in the initial sample set to obtain a sample set concentrated in the age group;

[0052] S103. The mean age of the patients in the sample set in the age group is taken as the mean age of the initial patients in the region;

[0053] S104, calculating the mean value of the nitrosamine compound content in the saliva of the patients in the sample set of the age group as the control value of the nitrosamine compound content of the patients in the region;

[0054] S105. For each patient in the initial sample set, the ratio of the nitrosamine compound content in the patient's saliva to the control nitrosamine compound content of patients in the region is used as the weight of the patient's dietary habits;

[0055] S106. Based on the weight of the dietary habits of each patient in the initial sample set, the dietary pathogenic factors of the region are quantified using the annual average of the content of initial patients in the region.

[0056] The expression of the mean age of the initial patients in the region in step S103 is:

[0057]

[0058] Among them, Y N1 is the mean age of the initial patients in the region; min_x N1 The minimum age of the initial patients in the region; max_x N1 is the maximum age of the initial patients in the region; num(x N1 ) is age x N1 The number of patients; x N1 is age; ε1 is the age balance coefficient.

[0059] The expression of the annual average value of the content of the initial patients in the region in step S106 is:

[0060]

[0061] in, Y is the annual average value of the content of initial patients in the region; N1 is the mean age of the initial patients in the region; min_x N1 The minimum age of the initial patients in the region; max_x N1 is the maximum age of the initial patients in the region; ε1 is the age balance coefficient; V i1 is the content of nitrosamine compounds in the saliva of the i1th patient in the initial sample set; N1 is the total number of patients in the initial sample set; i1 is the patient number in the initial sample set.

[0062] The correlation between various symptom combinations in the symptom set and esophageal cancer obtained in step S2 is specifically:

[0063] A1. Obtain a set of various symptom combinations in the symptom set, that is, a symptom combination sequence set;

[0064] A2. For each symptom combination in the symptom combination sequence set, obtain the ratio of the symptoms in the symptom combination that co-occur in the patients sampled in step S2 as the correlation between the symptom combination and esophageal cancer.

[0065] In this embodiment, the symptom combination sequence set does not include a symptom combination consisting of a single symptom and a symptom combination consisting of all symptoms in the symptom set; the symptom combinations include groups of two, three, four, etc.

[0066] The step S5 is specifically as follows:

[0067] S501, obtaining an initial symptom combination set according to possible combinations of various symptoms in the matching results;

[0068] S502, according to the initial symptom combination set, based on the correlations between various symptom combinations in the symptom set and esophageal cancer, obtaining the correlations between each symptom combination in the initial symptom combination set and esophageal cancer;

[0069] S503. Obtain the disease risk value of the subject to be examined according to the correlation between each symptom combination in the initial symptom combination set and esophageal cancer and the content of nitrosamine compounds in the saliva of the subject to be examined.

[0070] In this embodiment, the initial symptom combination is the same as the symptom combination in the symptom combination series set, and does not include a symptom combination consisting of a single symptom and a symptom combination consisting of all symptoms.

Claims

1. A method for assessing the risk of esophageal cancer, characterized in that: The following steps are involved: S1. Quantify the dietary pathogenic factors in the region based on the mean content of nitrosamine compounds in the saliva of early patients in the region; S2. Obtain the symptoms of patients in the early, middle and late stages, and perform principal component analysis to obtain a symptom set, and obtain the correlation between various symptom combinations in the symptom set and esophageal cancer; S3, obtaining the symptoms of the subject to be examined and the content of nitrosamine compounds in saliva; S4, matching the symptoms of the subject to be examined with the symptoms in the symptom set to obtain a matching result; S5. Obtain the disease risk value of the subject to be examined according to the matching result, the correlation between various symptom combinations in the symptom set and esophageal cancer, and the content of nitrosamine compounds in the saliva of the subject to be examined. When the disease risk value of the subject to be examined is greater than a preset risk threshold, the subject to be examined has a high risk of esophageal cancer; otherwise, the subject to be examined has a low risk of esophageal cancer. The expression of the disease risk value of the subject to be examined is: Wherein, P is the disease risk value of the subject to be examined; MMN is the normalization function; max is the maximum value function; R is the correlation between each symptom combination in the initial symptom combination set and esophageal cancer; V is the content of nitrosamine compounds in the saliva of the subject to be examined; Y is the age of the subject to be examined; It is the annual average value of the content in initial patients in the region.

2. The method for assessing esophageal cancer risk according to claim 1, characterized in that: The step S1 is specifically as follows: S101, obtaining sample data of N initial patients in a region to obtain an initial sample set; S102, based on age, remove discrete samples in the initial sample set to obtain a sample set concentrated in the age group; S103. The mean age of the patients in the sample set in the age group is taken as the mean age of the initial patients in the region; S104, calculating the mean value of the nitrosamine compound content in the saliva of the patients in the sample set of the age group as the control value of the nitrosamine compound content of the patients in the region; S105. For each patient in the initial sample set, the ratio of the nitrosamine compound content in the patient's saliva to the control nitrosamine compound content of patients in the region is used as the weight of the patient's dietary habits; S106. Based on the weight of the dietary habits of each patient in the initial sample set, the dietary pathogenic factors of the region are quantified using the annual average of the content of initial patients in the region.

3. The method for assessing esophageal cancer risk according to claim 2, characterized in that: The expression of the mean age of the initial patients in the region in step S103 is: Among them, Y N1 is the mean age of the initial patients in the region; min_x N1 The minimum age of the initial patients in the region; max_x N1 is the maximum age of the initial patients in the region; num(x N1 ) is age x N1 The number of patients; x N1 is age; ε1 is the age balance coefficient.

4. The method for assessing esophageal cancer risk according to claim 2, characterized in that: The expression of the annual average value of the content of the initial patients in the region in step S106 is: in, Y is the annual average value of the content of initial patients in the region; N1 is the mean age of the initial patients in the region; min_x N1 The minimum age of the initial patients in the region; max_x N1 is the maximum age of the initial patients in the region; ε1 is the age balance coefficient; V i1 is the content of nitrosamine compounds in the saliva of the i1th patient in the initial sample set; N1 is the total number of patients in the initial sample set; i1 is the patient number in the initial sample set.

5. The method for assessing esophageal cancer risk according to claim 1, characterized in that: The correlation between various symptom combinations in the symptom set and esophageal cancer obtained in step S2 is specifically: A1. Obtain a set of various symptom combinations in the symptom set, that is, a symptom combination sequence set; A2. For each symptom combination in the symptom combination sequence set, obtain the ratio of the symptoms in the symptom combination that co-occur in the patients sampled in step S2 as the correlation between the symptom combination and esophageal cancer.

6. The method for assessing esophageal cancer risk according to claim 1, characterized in that: The step S5 is specifically as follows: S501, obtaining an initial symptom combination set according to possible combinations of various symptoms in the matching results; S502, according to the initial symptom combination set, based on the correlations between various symptom combinations in the symptom set and esophageal cancer, obtaining the correlations between each symptom combination in the initial symptom combination set and esophageal cancer; S503. Obtain the disease risk value of the subject to be examined according to the correlation between each symptom combination in the initial symptom combination set and esophageal cancer and the content of nitrosamine compounds in the saliva of the subject to be examined.

Images